Clinical Trials Logo

Macular Edema clinical trials

View clinical trials related to Macular Edema.

Filter by:

NCT ID: NCT02731911 Completed - Clinical trials for Diabetic Macular Oedema

Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study

Start date: April 29, 2016
Phase:
Study type: Observational

This prospective study will assess Ozurdex in the treatment of Diabetic Macular Oedema in clinical practice.

NCT ID: NCT02712008 Completed - Clinical trials for Diabetic Macular Edema

Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema

RUBY
Start date: March 2, 2016
Phase: Phase 2
Study type: Interventional

The primary objective of the study was to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI) in improving best corrected visual acuity (BCVA) in participants with diabetic macular edema (DME).

NCT ID: NCT02699450 Completed - Clinical trials for Diabetic Macular Edema

A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema

BOULEVARD
Start date: April 27, 2016
Phase: Phase 2
Study type: Interventional

This is a multiple-center, multiple-dose, randomized, active comparator-controlled, double-masked, three parallel group, 36-week study in participants with center-involving diabetic macular edema (DME). Only one eye will be selected as the study eye. Where both eyes meet all eligibility criteria, the eye with the worse best corrected visual acuity (BCVA) will be defined as the study eye. The study will consist of a treatment period (20 weeks) and an observational period (up to 16 weeks). Treatment naive participants will be randomized in a 1:1:1 ratio to one of the Arms A, B and C, respectively. Participants previously treated with intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) will be randomized in a 1:1 ratio to Arms A and C.

NCT ID: NCT02698566 Completed - Macular Edema Clinical Trials

A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)

Start date: March 21, 2016
Phase: Phase 3
Study type: Interventional

This is a multicenter study designed to evaluate usability of ranibizumab PFS in patients with neovascular age related macular degeneration or macular edema secondary to retinal vein occlusion.

NCT ID: NCT02663141 Completed - Clinical trials for Diabetic Macular Edema

Randomized Clinical Trial of Intravitreal Bevacizumab Versus Intravitreal Bevacizumab Combined With Losartan in the Treatment of Diabetic Macular Edema

Start date: June 2015
Phase: Phase 2
Study type: Interventional

The aim of this study is to determine whether oral losartan is effective in the treatment of diabetic macular edema (DME) as an adjuvant for intravitreal bevacizumab (IVB).

NCT ID: NCT02661711 Completed - Clinical trials for Retinitis Pigmentosa

Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study

AMOUR
Start date: March 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of intravitreal injections of Aflibercept (Eylea) in treating Cystoid Macula Oedema (CMO) in patients with underlying Retinitis Pigmentosa (RP).

NCT ID: NCT02646670 Completed - Retinal Diseases Clinical Trials

Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema

Start date: July 2015
Phase: Phase 4
Study type: Interventional

The purpose of this study in to compare the efficacy of treatment of diabetic macular edema (DME) using Ranibizumab (Lucenti®), Aflibercept (Eylea®) and Aflibercept (Eylea®) plus Ranibizumab (Lucentis®). It is a randomized clinical trial that will evaluate the efficacy of the combination of two substances currently used in the treatment of DME. Will be allocated in different four groups randomly pacients who receive treatment with intravitreal injections of ranibizumab, aflibercept or a combination of aflibercept and ranibizumab.

NCT ID: NCT02646072 Completed - Diabetes Mellitus Clinical Trials

Effect of Preoperative Topical Ketorolac on Aqueous Cytokine Levels and Macular Thickness in Cataract Surgery Patients

Start date: August 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether there is a relationship between inflammatory cytokines in the aqueous of the eye and thickness of the macula after treatment of topical ketorolac for patients undergoing cataract surgery.

NCT ID: NCT02645747 Completed - Clinical trials for Retinal Vein Occlusion

Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion

RETRO CRVO
Start date: January 21, 2016
Phase:
Study type: Observational

The objective of this retrospective chart review is to evaluate drug utilization, usage patterns and indication of effectiveness Eylea in the routine clinical (real-life) management of patients who suffer from ME (Macular Edema), secondary to CRVO (Central Retinal Vein Occlusion), and who started treatment with Eylea for this indication.

NCT ID: NCT02639507 Completed - Clinical trials for Diabetes With Diabetic Retinopathy With Macular Edema

International Consortium Investigating Early Vitrectomy in Diabetic Macular Edema Patients

ICV-DME
Start date: June 2015
Phase:
Study type: Observational

The purpose of this research is to evaluate the effectiveness of vitrectomy for the treatment of diabetic macular edema. Diabetes is known to cause retinal blood vessels to leak, leading to swelling of the central retina (macula), and decreased vision. Removing the vitreous gel with vitrectomy surgery is known to decrease the swelling caused by diabetes. Diabetic retinopathy is often treated with laser or injections of medicine in to the eye.